Parkinson’s U.K., one of the world’s largest charity funders of Parkinson’s research, and Critical Path Institute (C-Path), an Arizona-based nonprofit organization dedicated to accelerating the pace and reducing the costs of medical product development, have formed the Critical Path for Parkinson’s Consortium (CPP).
The consortium will bring together pharmaceutical companies and academic partners working toward a common goal of establishing best practices and more efficient protocols for planning and designing clinical trials in early Parkinson’s—ultimately improving the efficiency and success rates of much-needed treatments for people with Parkinson’s.
Together, Parkinson’s U.K. and C-Path can maximize the benefit of data-sharing, which is critical for a condition such as Parkinson’s, for which there are no effective treatments.
“In the era of electronic knowledge exchange, only when data-sharing becomes the norm can we derive its full benefits,” said UCSF Cancer Bio-informatics Director Sue Dubman, a patient advocate and Parkinson’s patient.
Parkinson’s U.K. Chief Executive Steve Ford said, “Despite huge scientific progress, there have been no major advances in the treatments available for Parkinson’s in the last decade.
The new consortium will be co-directed by Dr. Arthur Roach, director of research at Parkinson’s U.K., and Dr. Diane Stephenson, executive director of the CPP.